Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs TJX Companies Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while TJX Companies Inc trades at $143.67 (market cap $157.11B). The key difference: TJX Companies Inc is far larger — about 21.4× Spyre Therapeutics Inc. Common Stock's market cap, and TJX Companies Inc pays a 1.34% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and TJX Companies Inc for 97 Days on average.
| SYRE | TJX | |
|---|---|---|
Market Cap | $7.35B | $157.11B |
Volume | 1,624,631 | 5,063,197 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $168.41 |
52-Week Low | $22.18 | $122.84 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $6.35B | $165.42B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TJX trades at $141.49, down 0.3% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $56.36 billion in 2025, with net income of $4.86 billion and a net margin of 8.63%. Recent earnings beats and a consensus analyst price target of $174.15 suggest potential upside, while robust cash flow and a high ROE of 62.17% highlight operational strength.
The stock presents a favorable risk-reward profile with Wall Street overwhelmingly bullish (85% buy ratings), though elevated valuation multiples and overbought RSI readings warrant caution. Key risks include competitive pressures in off-price retail and macroeconomic sensitivity, but TJX's consistent execution and growth trajectory support a positive outlook for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
